Bristol Myers Squibb (BMY) valuation
Bristol Myers Squibb P/E ratio history
Bristol Myers Squibb trades at 13.8 times its earnings over the last twelve months and 9.5 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 13.3 (year to Dec 2023) to 103.9 (year to Dec 2017), with a median of 21.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $53.94 | $3.46 | 15.6 | 8.8 |
| Dec 31, 2024 | $56.56 | -$4.41 | n/m | — |
| Dec 31, 2023 | $51.31 | $3.86 | 13.3 | 7.0 |
| Dec 31, 2022 | $71.95 | $2.95 | 24.4 | 9.2 |
| Dec 31, 2021 | $62.35 | $3.12 | 20.0 | 8.0 |
| Dec 31, 2020 | $62.03 | -$4.01 | n/m | — |
| Dec 31, 2019 | $64.19 | $2.19 | 29.3 | — |
| Dec 31, 2018 | $51.98 | $3.01 | 17.3 | — |
| Dec 31, 2017 | $61.28 | $0.59 | 103.9 | — |
| Dec 31, 2016 | $58.44 | $2.65 | 22.1 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Bristol Myers Squibb valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Bristol Myers SquibbBMY | $128B | 13.8 | 9.5 | 2.6 |
| PfizerPFE | $174B | 40.2 | 10.5 | 2.7 |
| Novo NordiskNVO | $178B | 9.9 | — | 3.5 |
| MerckMRK | $369B | 119.6 | 25.0 | 5.6 |
| ZoetisZTS | $33.4B | 13.0 | 12.6 | 3.5 |
| Johnson & JohnsonJNJ | $658B | 41.5 | 23.8 | 6.6 |
| ViatrisVTRS | $22.2B | — | 7.3 | 1.5 |
| Eli LillyLLY | $1.33T | 46.0 | 31.0 | 15.4 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| Peer median | 41.5 | 23.8 | 4.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: BMY financials · BMY returns
No forecast, no recommendation. This page describes Bristol Myers Squibb from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.